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Abstract
Programmed cell death 1 (PD-1) signal receptor blockade has revolutionized the field of cancer therapy. Despite their consid-
erable potential for treating certain cancers, drugs targeting PD-1 still present two main drawbacks: the substantial number 
of unresponsive patients and/or patients showing recurrences, and side effects associated with the autoimmune response. 
These drawbacks highlight the need for further investigation of the mechanisms underlying the therapeutic effects, as well 
as the need to develop novel biomarkers to predict the lack of treatment response and to monitor potential adverse events. 
Combination therapy is a promising approach to improve the efficacy of PD-1 blockade therapy. Considering the increasing 
number of patients with cancer worldwide, solving the above issues is central to the field of cancer immunotherapy. In this 
review, we discuss these issues and clinical perspectives associated with PD-1 blockade cancer immunotherapy.
Keywords Immune checkpoint inhibitor · Biomarker · Immune-related adverse event · Immune metabolism · Combination 
therapy
History of cancer immunology: basic 
to clinical research
The hypothesis that most cancer cells are eliminated by the 
host immune system during cancer development is known as 
“immunological surveillance”; this concept was proposed by 
Burnet in the 1960s. However, this theory failed to explain 
the reasons for cancer proliferation despite immunological 
surveillance. In 2002, Dunn et al. referred to “cancer immu-
noediting”, which comprises three stages: the “elimination 
phase”, “equilibrium phase”, and “escape phase” [1]. In the 
elimination phase, abnormally proliferating cells are elimi-
nated via immunological surveillance. Abnormally prolif-
erating cells that are not eliminated enter the precancerous, 
equilibrium phase in which apparent tumor size remains 
unchanged, as the rate of elimination by immune cells is 
equal to the proliferation rate of abnormal cells. However, 
once abnormal cells have acquired mechanisms that allow 
them to escape immunological surveillance, they enter the 
escape phase, where a growing mass is recognized as cancer. 
Anti-tumor immunity involves various immune cells, but 
the final effector cells are cytotoxic T lymphocytes (CTLs), 
which specifically recognize and kill diverse antigens 
expressed on cancer cells. Cancer immune escape involves 
the loss of tumor antigen, human leukocyte antigen (HLA), 
and expression of immunosuppressive molecules in tumor 
cells, as well as induction of immunosuppressive cells.
Programmed cell death 1 (PD-1) is an immunosup-
pressive co-stimulatory signal receptor that belongs to 
the CD28 family. PD-1 was first identified by Ishida et al. 
in 1992 as a programmed cell death-induced gene encod-
ing type I membrane proteins in T cells (Fig. 1) [2]. PD-1 
was shown to be an immune suppressive factor based on 
the development of autoimmune diseases in PD-1 recep-
tor-deficient mice [3-6]. PD-1 is expressed primarily on 
activated T cells and B cells, and serve as an immune 
regulator that controls inappropriate and extreme immune 
responses such as autoimmune and excessive infectious 
immune responses. It suppresses antigen receptor activa-
tion by PD-ligand 1 (PD-L1) and PD-L2, which belong 
to the co-stimulatory signal B7 family. Although PD-L1 
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is widely expressed on antigen-presenting cells (dendritic 
cells, blood vessels, myocardium, lung, and placenta), 
PD-L2 is present on dendritic cells and is only expressed 
in activated macrophages. Binding of PD-1 to PD-L1/2 is 
primarily related to immunosuppression in the peripheral 
tissue. Indeed, PD-L1-introduced tumors grow quickly in 
wild-type mice but not in PD-1-knockout mice, indicating 
that PD-1 plays a central role in cancer cell immune escape 
mechanisms [7]. Based on the hypothesis that interruption 
of anti-PD-1/PD-L1 binding may activate T cells against 
cancer cells, PD-1 blocking antibodies have been devel-
oped as immune checkpoint inhibitors for cancer therapy 
[7] (Fig. 1).
The clinical efficacy of nivolumab, an antibody against 
human PD-1, was subsequently reported in 2010 and 2012 
[8, 9]. In 2014, nivolumab was approved in Japan for the 
treatment of malignant melanoma for the first time world-
wide. PD-1/PD-L1 antibody-based therapy is currently 
approved for the treatment of various cancers (Fig.  1). 
However, more than half of patients do not respond to this 
therapy [10].
Improving the response rate in patients with cancer 
relies on three different approaches: (1) elucidating the 
mechanisms underlying the lack of response to PD-1 anti-
body treatment, (2) developing novel predictive mark-
ers, and (3) developing an effective combination therapy. 
These approaches and the status of current research are 
discussed in the subsequent sections.
Biomarkers
Killer T cells are the final effector immune cells that attack 
cancer cells. Killer T cell activity cannot be predicted by 
any single biomarker as it is controlled by various factors 
(Fig. 2), including tumor- and immune-related factors, as 
well as environmental factors such as enterobacteria and 
metabolism.
Fig. 1  History of programmed cell death-1 (PD-1) blockade cancer immunotherapy development
792 International Journal of Clinical Oncology (2020) 25:790–800
1 3
Biomarkers‑tumor‑related factors
A nivolumab phase I clinical study revealed that PD-L1 
expression in tumor cells may be an indicator of treatment 
efficacy [8]. Several clinical trials subsequently evaluated 
whether PD-L1 expression could be a predictive biomarker. 
However, a significant association between improved out-
comes and PD-L1 expression was observed only in cer-
tain cancers [11]. According to clinical studies showing 
a positive association, the United States (US) Food and 
Drug Administration (FDA) approved pembrolizumab for 
the treatment of PD-L1-positive non-small cell lung cancer 
(NSCLC), gastric or gastroesophageal junction cancer, and 
cervical cancer in 2015, 2017, and 2018, respectively. Fur-
thermore, considering IMpassion130 study results, the FDA 
approved therapy with atezolizumab (a PD-L1 antibody) 
and chemotherapy (nab-paclitaxel) for PD-L1-positive and 
metastatic triple-negative breast cancer (TNBC) in March 
2019 [12].
Two main mechanisms are hypothesized to be involved 
in PD-L1 expression in tumors: forced expression of PD-L1 
due to translocations or mutations [13], and stimulation of 
intra-tumoral T cell-produced interferon, also known as 
“adaptive resistance” [14-16]. Because adaptive resistance 
is regulated by immune cell activity, PD-L1 expression 
show a correlation with PD-1 blockade therapy prognosis. 
However, insufficiency of tumor PD-L1 expression as a 
biomarker may result from difficulties in distinguishing the 
above two mechanisms. Moreover, PD-1/PD-L1 expression 
in tumor-infiltrating immune cells (T cells and macrophages) 
is reported to be involved in the therapeutic effects in malig-
nant melanoma or bladder cancer [15, 17-19].
PD-1 antibodies are effective for tumors with somatic 
mutations, such as malignant melanoma, lung cancer, and 
renal cell carcinoma (RCC) [20]. Tumor-infiltrating T cells 
recognize mutated peptides as foreign antigens (neoanti-
gens), thus inducing a strong immune response. Rizvi et al. 
demonstrated a significant correlation between therapeutic 
effect and neoantigen number, DNA repair pathway muta-
tions, and non-synonymous mutations in pembrolizumab-
treated patients with NSCLC [21]. In the CheckMate 026 
study (phase III), which used nivolumab as first-line NSCLC 
treatment, high tumor mutational burden (TMB) tumors 
were likely to show greater responses [22]. However, another 
study reported a partial response even in low-TMB RCC 
[23]. This suggests the importance of the mutation type in 
addition to the number, as RCC frequently contains indel 
mutations (DNA insertion and deletion), which produce 
frameshift and variety of neo-antigens [23]. Future studies 
are needed to measure and evaluate the type and number of 
mutation, which affect the efficacy.
A phase II study evaluated the effect of pembrolizumab 
(NCT01876511) in colorectal cancer with deficiency of 
DNA mismatch repair (MMR) ability (dMMR), those with 
functional MMR protein expression, and all solid tumors 
with dMMR. Therapeutic efficacy was low in colorectal 
cancer with MMR protein expression, but was high in all 
solid tumors with dMMR [24]. Whole-exome sequencing 
Fig. 2  Regulation of killer T 
cell activity by various factors 
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showed that the average number of somatic mutations per 
tumor with dMMR and tumors with functional MMR (1782 
and 73, respectively) was significantly correlated with thera-
peutic effect. Moreover, the number of neoantigen-specific 
T cells in responding patients was significantly higher than 
that in non-responders in the NCT01876511 study. Accord-
ingly, the FDA approved pembrolizumab in May 2017 for 
unresectable/metastatic solid cancers with high microsatel-
lite instability (MSI-H) or dMMR in adults and children. 
Furthermore, the FDA approved nivolumab and the com-
bination of nivolumab and ipilimumab in August 2017 and 
in July 2018, respectively, for MSI-H or dMMR metastatic 
colorectal cancer [25]. It is the first time that a treatment has 
been approved based on the biomarker rather than tumor 
type [26].
Biomarkers‑immunity‑related factors
Higher numbers of tumor-infiltrating CTLs are correlated 
with better prognosis. This is known as the “immunoscore” 
[27, 28], in which  CD8+ T cell quantification at the tumor 
center and periphery can strongly predict the overall survival 
(OS) and well correlated with the traditional tumor-node-
metastasis (TNM) staging and/or MSI status in patients with 
colorectal cancer [28-30]. Moreover, the number of  CD8+ T 
cells around the tumor was correlated with therapeutic effect 
in PD-1 antibody-treated patients with malignant melanoma 
treated [16]. The number of infiltrated  CD8+ T cells was also 
correlated with high PD-L1 expression in tumor cells and 
the therapeutic effect of PD-1 antibodies [31]. However, the 
immunoscore is not a perfect marker as the significance of 
CTL tumor infiltration may vary depending on the type of 
carcinoma. For instance, in the case of RCC, higher numbers 
of tumor-infiltrating  CD8+ T cells are correlated with poor 
prognosis [32].
Since tumor tissue biopsy may be extremely invasive, the 
use of less invasive biomarkers, such as those in peripheral 
blood, would represent an ideal approach. High neutrophil/
lymphocyte ratio (NLR), which is typically measured in 
conventional blood tests, is associated with poor prognosis 
in cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody-
treated patients with malignant melanoma [33] and in PD-1 
antibody-treated patients with various cancer [34, 35].  CD4+ 
T cells increase in the periphery is reported to be related 
to good response after nivolumab treatment [36, 37]. Cells 
release extracellular exosomes containing their surface mol-
ecules [38, 39]. While an increase in circulating exosomal 
PD-L1 in the blood before anti-PD-1antibody treatment was 
associated with poor response in patients with melanoma 
[38], increased PD-1 and CD28 expression in exosomes, 
which may be derived from T cells, was associated with 
improved progression-free survival (PFS) in anti-CTLA4-
treated patients [40]. Instead of many ongoing researches, 
no peripheral blood biomarker for immune-related factors 
has been approved by the FDA for clinical use.
Biomarkers‑microbiota
More than 1000 microorganism species and 100 trillion bac-
teria coexist in the human body. The maturation and barrier 
function of the immune system were significantly impaired 
in germ-free and antibiotic-treated mice. This immune 
impairment is normalized by transplanting mouse intesti-
nal bacteria. The intestinal microbiota produces metabolites 
(such as short-chain fatty acids) from indigestible polysac-
charides. The short-chain fatty acid butyric acid regulates 
immunity and metabolism by binding to G-protein-coupled 
receptors and promoting epigenome modifications [41]. A 
significant correlation between PD-1 blocking treatment effi-
cacy and enterobacteria (i.e., Bifidobacterium) levels was 
reported in a mouse model of melanoma B16 cells, suggest-
ing the potential of microbiota composition as a predictive 
biomarker for PD-1 blockade therapy [42].
Routy et al. reported the effects of antibiotics on the 
response to immune checkpoint inhibitors in patients with 
NSCLC, RCC, and urothelial carcinoma [43]. PFS and OS 
significantly decreased after PD-1/PD-L1 antibody treatment 
in patients with a history of antibiotic treatment compared 
to those in patients without. Intestinal microbiota damage 
caused by antibiotics may therefore attenuate the anti-tumor 
immune response to immune checkpoint inhibitors. Moreo-
ver, intestinal microbiota composition differed between 
PD-1 antibody treatment responders and non-responders, 
and patients with a high proportion of Akkermansia mucin-
iphila species in their microbiome showed better treatment 
outcomes. A significant correlation between type 1 T helper 
(Th1) responses to bacteria and treatment outcome has also 
been demonstrated [43]. Gopalakrishnan et al. and Matoson 
et al. investigated intestinal microbiota composition in PD-1 
antibody-treated patients and found a significant correlation 
between enterobacteria diversity and responsiveness to treat-
ment [44, 45]. Furthermore, a recent study reported that 11 
types of enterobacteria isolated from healthy individuals’ 
feces led to  CD8+ T cell activation, and that mice inocu-
lated with these bacteria species showed greater tolerance 
to infection and anti-cancer immune responses [46]. Over-
all, studying crosstalk between the intestinal microbiome 
and the immune system would be useful for both potential 
biomarker candidate discovery and effective combination 
therapy development.
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Side effects
Immune checkpoint inhibitors may cause fewer adverse 
events than conventional chemotherapy (Table 1) [10, 47-
49]. It is of note that PD-1 antibodies generate less severe 
side effects than CTLA-4 antibodies [50, 51]. Combination 
therapy with PD-1 antibodies and chemotherapy showed 
side effects similar to those of chemotherapy alone, 
whereas combination therapy with PD-1 and CTLA-4 
antibodies may cause side effects more severe than those 
associated with either monotherapy (Table 1) [51-53]. 
Immune checkpoint inhibitor treatment requires precau-
tions because of potential immune-related adverse events 
(irAEs), which differ from the adverse events observed 
during conventional chemotherapy. irAEs include rash 
with itching, diarrhea, enteritis, hepatitis, hypophysitis, 
thyroiditis, pneumonitis, type 1 diabetes, myositis, periph-
eral neuritis, and myasthenia gravis. Although many of 
the side effects are mild, reversible, and easy to treat, it 
is important to be aware of potential sever irAEs and cor-
responding treatment.
Treatment for irAEs relies on diagnosis to exclude non-
inflammatory diseases, followed by a treatment to reduce 
symptoms, steroid treatments, or administration of the 
anti-tumor necrosis factor (TNF)-α antibody infliximab 
depending on symptom severity [10, 54].
Although most side effects are not severe, they often 
include asymptomatic endocrine consequences. Early 
detection and intervention are essential to reduce the risk 
of irAE-related side effects. Steroid treatment for irAEs 
has been reported to improve symptoms, although in some 
cases, anti-tumor immunity persists [55, 56], perhaps 
because of stronger immune responses to cancer antigens 
than to autoantigens. Therefore, in certain patients steroids 
do not sufficiently suppress immune responses to tumors, 
but is enough to inhibit autoimmune responses. Further 
studies are required to monitor autoimmune responses 
without impairing anti-tumor immunity and develop bio-
markers that predict fatal side effects.
Table 1  Grade 3–5 adverse event related with treatment in phase III clinical trials of PD-1 antibody
NSCLC non-small cell lung cancer, PD-L1 programmed cell death ligand 1
a Original sources are given as reference numbers
b Four cycles of the investigator’s choice of intravenously administered cisplatin 75 mg/m2 or carboplatin (area under the concentration–time 
curve, 5 mg/mL/min) plus pemetrexed (500 mg/m2), all administered intravenously every 3 weeks, followed by pemetrexed 500 mg/m2 every 
3 weeks
c Carboplatin (at a dose calculated to obtain an area under the concentration–time curve of 6 mg/mL/min) on day 1 and either paclitaxel 200 mg/
m2 on day 1 or nab-paclitaxel 100 mg/m2 on days 1, 8, and 15
Clinical study Tumor Drugs Cases Incidence of grade 3–5 adverse 
event related with treatment (%)




KEYNOTE-006 [50] Advanced melanoma Pembrolizumab every 2 week 278 13.3
Pembrolizumab every 3 week 277 10.1
Ipilimumab 256 19.9
CheckMate 067 [51] Untreated stage III or IV melanoma Nivolumab alone 313 16.3
Ipilimumab alone 311 27.3
Nivolumab plus ipilimumab 313 55.0
CheckMate 017 [47] Advanced squamous-cell NSCLC Nivolumab 131 7
Docetaxel 129 55
CheckMate 057 [48] Advanced non-squamous NSCLC Nivolumab 287 10
Docetaxel 268 54
KEYNOTE-189 [49] Previously treated NSCLC with PD-L1 
expression on at least 1% of tumor cells
Pembrolizumab 2 mg/kg 339 13
Pembrolizumab 10 mg/kg 343 16
Docetaxel 309 35
KEYNOTE-189 [52] Metastatic non-squamous NSCLC with-
out sensitizing EGFR or ALK mutations
Pembrolizumab plus  chemotherapyb 410 67.2
Chemotherapyb 206 65.8
KEYNOTE-407 [53] Untreated metastatic, squamous-cell 
NSCLC cancer
Pembrolizumab plus  chemotherapyc 278 69.8
Chemotherapyc 281 68.2
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Tolerance to PD‑1 blockade therapy
Although PD-1/PD-L1-blocking antibodies have longer 
therapeutic effects than conventional chemotherapy, resist-
ance may occur. Zaretsky et al. analyzed biopsy specimens 
from four patients who first experienced tumor reduction 
prior to progression several years after pembrolizumab 
treatment. Whole-exome sequencing was performed on 
pairs of biopsy specimens before and after the treatment 
and revealed interferon receptor-related Janus kinase 
(JAK)1/JAK2 mutations in two of four patients, as well as 
mutations of histocompatibility complex (MHC) class I 
expression in another patient [57]. Shin et al. showed that 
malignant melanoma and dMMR colorectal cancer with 
JAK1/JAK2 mutations led to initial pembrolizumab treat-
ment resistance despite the high number of somatic muta-
tions. In the study, they demonstrated that JAK function 
loss, which inactivates the interferon signaling pathway, 
is involved in the impairment of antigen presentation in 
tumor cells [58]. Anagnostou et al. analyzed four patients 
with NSCLC who became refractory after receiving 
combination therapy with PD-1 and CTLA-4 antibodies. 
Mutation-related neoantigens were reduced in size after 
resistance acquisition and were involved in resistance to 
checkpoint inhibitors [59]. Gong et al. performed tumor 
gene analysis in 17 patients who had acquired tolerance 
to PD-L1 antibodies and identified secreted RNA splicing 
of PD-L1 protein variants in four patients, which com-
petitively neutralized anti-PD-L1 antibody activity [60]. 
Although all analyses were performed on a relatively small 
sample, these findings promote the development of effec-




The effects of typical cytotoxic anticancer drugs on anti-
tumor immune responses are well known. Combination 
may improve the effect of immune checkpoint inhibitors 
via dendritic cell activation with increased neoantigen 
presentation, MHC upregulation, and inhibition of immu-
nosuppressive cell activity [including regulator T cells 
(Tregs), M2 macrophages, and myeloid-derived suppres-
sor cells (MDSC)] [61-63]. In the KEYNOTE-021 clinical 
study (phase II), patients with PD-L1-positive non-squa-
mous NSCLC without epidermal growth factor receptor 
(EGFR) mutations or anaplastic lymphoma kinase (ALK) 
genetic translocation were tested with pembrolizumab and 
chemotherapy (carboplatin and pemetrexed). Patients were 
divided into three groups: pembrolizumab and chemo-
therapy group (combination therapy), maintenance ther-
apy group, and chemotherapy only group. The response 
rates were 29% and 55% in the chemotherapy alone and 
combination therapy groups, respectively. Accordingly, 
the FDA approved combination therapy with pembroli-
zumab and chemotherapy for NSCLC in May 2017. In 
the KEYNOTE-189 and KEYNOTE-407 studies (phase 
III), PFS and OS were significantly longer in patients 
treated with pembrolizumab and chemotherapy than that 
in patients treated with chemotherapy alone. The FDA 
therefore extended indications for pembrolizumab and 
chemotherapy combination therapy [52, 53]. Moreover, 
the IMpower150 study (phase III) showed that PFS was 
longer in the combination therapy group (with chemo-
therapy/angiogenesis inhibitor bevacizumab), resulting 
in FDA approval for NSCLC in December 2018 [64]. 
In the IMpower133 study (phase III), atezolizumab and 
chemotherapy (carboplatin and etoposide) significantly 
prolonged both PFS and OS in patients with extensive 
stage small cell lung cancer, resulting in FDA approval 
of this combination as first-line therapy in March 2019 
[65]. In addition, in the IMpassion130 study (phase III), 
atezolizumab and albumin-bound paclitaxel resulted in 
significantly longer PFS than that in the chemotherapy 
only group, leading to FDA approval for TNBC in March 
2019 [12]. It is well known that angiogenesis supports the 
tumor growth. Vascular endothelial growth factor (VEGF) 
inhibitor inhibits the tumor growth by attenuating the angi-
ogenesis or normalized aberrant vessel structure [66]. It is 
noticeable that VEGF receptor tyrosine kinase inhibitor, 
Axitinib combined with PD-1 blockade has improved the 
survival of patients with advanced renal-cell carcinoma 
and approved by FDA though the precise mechanisms 
remains unknown [67, 68].
Overall, these clinical studies support the enhanced 
efficacy of combination therapy with chemotherapy and 
immune checkpoint inhibitors. Considering that monother-
apy with immune checkpoint inhibitors also showed signifi-
cant therapeutic effects in a substantial subset of patients, the 
development of novel biomarkers is necessary to distinguish 
patients requiring only monotherapy from those requiring 
combination therapy.
Combination with CTLA‑4 antibodies
Other immune checkpoint molecules, such as CTLA-4, 
T cell immunoglobulin mucin 3 (Tim3), and lymphocyte 
activation gene 3 (LAG3), function as immune brakes 
and blocking antibodies for these molecules are therefore 
called immune checkpoint inhibitors. CTLA-4 antibod-
ies were first developed in the 1990s [69]. A clinical trial 
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reported that patients treated with the CTLA-4 antibody 
ipilimumab showed good treatment outcomes. In 2011, 
the FDA approved CTLA-4 antibodies as therapeutic 
agents for malignant melanoma. Combining the therapeu-
tic effects of PD-1 and CTLA-4 blockade appears logi-
cal because of their different targets and mechanisms of 
action. Dendritic cells activate CTLs by presenting tumor 
antigens in lymph nodes, leading to the elimination of 
cancer cells expressing the same antigens. In the early 
phase of T cell priming, CD28 located on T cells were 
bound to B7 (CD80 and CD86) on dendritic cells in addi-
tion to the interaction between T cell receptor and MHC. 
CTLs prevent excess activation via the B7 receptor CTLA-
4, which binds to B7 with approximately 20 times more 
affinity than CD28, resulting in the CD28 signal blockade. 
CTLA-4 antibodies recover T cell activation by block-
ing the competition with CD28 [70]. CTLA-4 antibodies 
enhance anti-tumor activity by suppressing Treg activity 
or reducing the number of Tregs in the tumor tissue via 
antibody-dependent cellular cytotoxicity (ADCC) due to 
CTLA-4 overexpression on Tregs [71-73]. However, pre-
cise mechanisms remain unclear.
In the CheckMate 069 (phase II) and CheckMate 067 
(phase III) studies for malignant melanoma patients, combi-
nation therapy with ipilimumab (human CTLA-4 antibody) 
and nivolumab significantly prolonged PFS compared with 
each alone, resulting in FDA approval of this combination 
therapy [51, 74]. However, the incidence of irAEs was rela-
tively high (Table 1). The long-term follow-up data in the 
CheckMate-067 study revealed that the frequency of the 
patients who required discontinuation of the therapy due 
to severe irAEs was 30%, 8%, and 40% in the ipilimumab-
nivolumab combination therapy, nivolumab treatment, and 
ipilimumab treatment, respectively. Moreover, the incidence 
of side effects of ≥ grade 3 was 59%, 21%, and 28%, respec-
tively [75]. In the CheckMate 214 study (phase III) of RCC, 
which compared combination therapy with ipilimumab-
nivolumab and standard treatment, the combination therapy 
group showed significantly longer OS and higher response 
rate [76]. However, certain patients in the sunitinib group 
who were classified as patients with “favorable risk” (good 
prognosis) according to the International Metastatic Renal 
Cell Carcinoma Database Consortium (IMDC) risk classifi-
cation showed better outcomes than patients with the combi-
nation therapy. Therefore, in April 2018, the FDA approved 
combination therapy with ipilimumab and nivolumab for 
intermediate-/poor-risk patients (poor prognosis) in IMDC 
classification with untreated advanced RCC [76].
The efficacy of combination therapy with ipilimumab and 
nivolumab in patients with NSCLC was confirmed by the 
CheckMate-227 study [77]. In this study including patients 
with high TMB, the ipilimumab-nivolumab combination 
therapy group showed significantly longer PFS than the 
standard treatment group [77]. Treatment with a combina-
tion of PD-1 and CTLA-4 antibodies shows promise if irAEs 
are well controlled and if predictive biomarkers for irAEs 
are developed.
Improvement of cancer immunotherapy 
via metabolic control
Mitochondria play a central role in energy metabolism. 
Mitochondria-based lipid metabolism and oxidative phos-
phorylation are considered crucial in the formation and 
maintenance of memory T (Tm) cells [78]. Buck et  al. 
reported that mitochondrial morphological changes led to 
metabolic reprogramming, thereby controlling T cell dif-
ferentiation. Effector T (Te) cells showed small, distinct 
mitochondria widely dispersed in the cytoplast whereas 
Tm cells had densely fused mitochondria. Moreover, forced 
expression of Opa1, a gene required for mitochondrial 
fusion, induced Tm cell differentiation, suggesting that mito-
chondrial metabolism determines T cell differentiation [79]. 
We showed that mitochondrial activation in tumor-reactive 
CTLs during PD-1-blocking antibody therapy increased 
mitochondrial production of reactive oxygen species (ROS) 
[80]. Furthermore, medication promoting ROS production 
and metabolism-related substances activating mitochondria 
enhanced PD-1 blockade cancer immunotherapy. In these 
models, mammalian target of rapamycin (mTOR) and 5′ 
adenosine monophosphate-activated protein kinase (AMPK) 
were both activated in tumor-reactive T cells, and the activa-
tion of these related signals by low-molecular weight com-
pounds increased the therapeutic efficacy of PD-1-blocking 
antibody therapy (Fig. 3). Importantly, peroxisome prolif-
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Fig. 3  Low-molecular weight drugs activating reactive oxygen spe-
cies (ROS) production mTOR/AMPK, or PPAR gamma coactivator-
1α (PGC-1α) signaling pathways enhance anti-tumor immunity medi-
ated by PD-1 blockade
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(PGC-1α)/PPAR signals, which promote mitochondrial acti-
vation, were also activated in the downstream. Tumor inhib-
itory effects were therefore enhanced by the combination 
treatment with bezafibrate, a PGC-1α/PPAR complex ligand, 
which has been used for the treatment of hyperlipidemia  in 
the clinic (Fig. 3) [80]. Additionally, a significant increase 
in total energy metabolism (mitochondrial metabolism and 
glycolysis) via PGC-1α/PPAR signaling was observed in the 
T cells of mice receiving combination therapy with bezafi-
brate and PD-1-blocking antibodies. PGC-1α/PPAR sign-
aling induced high expression of carnitine palmitoyltrans-
ferase 1a (Cpt1a, a fatty acid oxidation-related gene) and 
B-cell lymphoma 2 (Bcl-2, an apoptosis inhibitory gene), 
which prevent T cells from activation-induced apoptosis 
[81]. These systems may convert tumor-reactive Te cells, 
which are supposed to be short-lived, into long-surviving 
Te cells, resulting in an overall increase of Te numbers 
and thus enhancing therapeutic efficacy. Scharping et al. 
reported low PGC-1α expression levels in exhausted T cells 
within a tumor microenvironment, although forced PGC-1α 
expression in T cells rescued cells from a state of exhaus-
tion via mitochondrial-related metabolic reprogramming and 
enhanced tumor inhibition [82]. Anti-tumor responses may 
therefore be improved by energy metabolism control via the 
mitochondria in T cells. The authors also investigated differ-
ences in the ability to induce a hypoxic tumor microenviron-
ment, which regulates responsiveness to immune checkpoint 
inhibitors, in a mouse model. Metformin, which is used to 
treat type 2 diabetes, suppressed intratumoral oxygen con-
sumption by tumor cells in vitro and in vivo, reduced the 
intratumoral hypoxic state, and improved intratumoral T cell 
function, when used in combination with PD-1 antibodies 
[83]. Bezafibrate and metformin cause fewer side effects and 
have been used to treat other diseases, suggesting the greater 
feasibility of combination therapy with these drugs and can-
cer immunotherapy.
Future perspectives
PD-1 antibodies have been rapidly developed after their 
introduction into cancer immunotherapy. However, treat-
ment efficacy varies widely according to cancer type, and 
treatment cannot be applied uniformly even to patients with 
the same cancer type. Overall, many challenges remain in 
the context of PD-1 antibody treatment. Further improve-
ment in cancer care relies on: (1) elucidation of the fun-
damental mechanisms explaining how PD-1 antibodies 
possess anti-tumor effects, (2) biomarker development for 
better prediction of therapeutic and side effects, and (3) the 
development of combination therapy with fewer side effects. 
Novel findings and strategies addressing the three issues 
mentioned here would ensure the improvement of cancer 
immunotherapy.
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